Jazz Pharmaceuticals has reported positive results from TONES 5 study, a Phase lll trial of solriamfetol for the treatment of excessive sleepiness (ES) in patients with narcolepsy or obstructive sleep apnea (OSA).

Findings of the open-label trial have showed solriamfetol’s long-term maintenance of efficacy and a tolerable safety profile in the enrolled patients.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

As part of the trial, 643 patients, including 226 narcolepsy and 417 OSA, were given solriamfetol and included in the safety population, and 458 completed the study.

A total of 282 patients entered the two-week, placebo-controlled, randomised withdrawal (RW) phase, and 280 completed this phase, representing the modified intent-to-treat population.

At the end of the RW phase, patients who received solriamfetol showed improvement, while those who were switched to placebo remained worsened.

“The trial had a two-week titration phase followed by a maintenance phase of up to 50 weeks.”

The primary endpoint in the RW phase included change in Epworth Sleepiness Scale (ESS) from beginning to end of the RW, while the secondary endpoints were patient and clinician global impression of change (PGI-C and CGI-C) respectively.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The trial had a two-week titration phase followed by a maintenance phase of up to 50 weeks.

Among the other results, the TONES 5 trial demonstrated long-term maintenance of efficacy during the open-label period for up to one year by sustained reductions in mean ESS scores and improvements on the PGI-C and CGI-C scales.

Jazz Pharmaceuticals Sleep and CNS Medicine senior vice-president Jed Black said: “If approved by the US Food and Drug Administration, solriamfetol would offer patients the first new chemical entity for the treatment of excessive sleepiness in narcolepsy and OSA in the US in nearly ten years.”

OSA is a prevalent disease where ES is a major presenting complaint in many cases.

ES in OSA is related to impairments in cognitive function, safety, productivity, interpersonal relationships, and overall quality of life.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact